BMP signaling mediates glioma stem cell quiescence and confers treatment resistance in glioblastoma

Rohit Sachdeva1, Megan Wu1, Kevin Johnson2, Hyunsoo Kim2, Angela Celebre3,4, Uswa Shahzad1,4, Maya Srikanth Graham5,6, John A. Kessler4, Jeffrey H. Chuang2, Jason Karamchandani7, Markus Bredel8, Roel Verhaak2 & Sunit Das1,3,4,9

Despite advances in therapy, glioblastoma remains an incurable disease with a dismal prognosis. Recent studies have implicated cancer stem cells within glioblastoma (glioma stem cells, GSCs) as mediators of therapeutic resistance and tumor progression. In this study, we investigated the role of the transforming growth factor-β (TGF-β) superfamily, which has been found to play an integral role in the maintenance of stem cell homeostasis within multiple stem cell systems, as a mediator of stem-like cells in glioblastoma. We find that BMP and TGF-β signaling define divergent molecular and functional identities in glioblastoma, and mark relatively quiescent and proliferative GSCs, respectively. Treatment of GSCs with BMP inhibits cell proliferation, but does not abrogate their stem-ness, as measured by self-renewal and tumorigenicity. Further, BMP pathway activation confers relative resistance to radiation and temozolomide chemotherapy. Our findings define a quiescent cancer stem cell population in glioblastoma that may be a cellular reservoir for tumor recurrence following cytotoxic therapy.
dysregulated in cancer and to direct multiple hallmarks of cancer, such as cell growth and survival, invasion and migration, and angiogenesis. In glioblastoma, ID1 knockdown in a mouse xenograft model impairs cell invasion and thereby results in increased overall survival. In colon cancer, knockdown of ID1 and ID3 have been shown to impair self-renewal of colon cancer tumor initiating cells, reduce tumor growth and enhance sensitivity to chemotherapy. Interestingly, ID1 ablation in a mouse transgenic glioblastoma model failed to render these cells non-tumorigenic; in fact, ID1 loss appeared to enhance tumor growth and shorten latency to end point.

There is growing evidence to suggest that the superfamily of transforming growth factor-β (TGF-β) play an integral role in the maintenance of stem cell homeostasis through their effects on ID1 expression within multiple stem cell systems. In the hair follicle stem cell niche, dampening of a repressive bone morphogenetic protein (BMP) signal by TGF-β is necessary for hair follicle stem cells to transition from the telogen (quiescent) to anagen (activated) state, a process that requires the suppression of BMP-mediated expression of ID1. Similarly, ID1 expression restrains proliferation and fate commitment in hematopoietic stem cells (HSCs), and is required for HSC repopulation and maintenance.

We postulated that BMP and TGF-β signaling could have an analogous role for human GSCs through their effect on ID1. Here, we report that BMP and TGF-β signaling define divergent molecular and functional identities in glioblastoma, and mark relatively quiescent and proliferative GSCs, respectively. Treatment of GSCs with BMP inhibits cell proliferation, but does not abrogate their stem-ness, as measured by self-renewal and tumorigenicity. Further, BMP pathway activation confers relative resistance to radiation and temozolomide chemotherapy. The development of temozolomide resistance results in selection of cells with prolonged cell-cycle time and latency of tumor formation. Finally, we find that p21 mediates the effect of BMP signaling on glioma cell proliferation and chemotherapeutic resistance. Our findings define a quiescent cancer stem cell population in glioblastoma that may be a potentially targetable cellular reservoir for tumor recurrence following cytotoxic therapy.

Results
BMP and TGF-β signaling define divergent molecular identities in glioblastoma. To determine if the BMP and TGF-β pathways are activated in glioblastoma cells in the tumor microenvironment, we performed immunohistochemistry on human glioblastoma specimens (n = 9) for the activated nuclear R-SMADs, pSmad1 (BMP) and pSmad2 (TGF-β). We found evidence of nuclear pSmad1 and pSmad2 staining in all molecular subtypes that we examined (Fig. 1A). To confirm that BMP and TGF-β activation was present in glioma cells rather than stromal non-neoplastic cells, we repeated these studies in a glioblastoma possessing an R132H IDH1 mutation, in which glioma cells can be differentiated from non-glioma cells by the presence of the IDH1 R132H mutation. Both pSmad1-positive and pSmad2-positive cell populations were IDH1-mutant, confirming their identity as glioma cells (Supplementary Fig. 1A, B).

As previous reports have shown that BMP signaling directs astroglial differentiation in GSCs, we expected that pSmad2-positive glioma cells would be enriched in stem cell markers, such as Sox2 and nestin, compared to pSmad1-positive glioma cells. Surprisingly, single-cell qRT-PCR analysis of pSmad1- and pSmad2-positive cells isolated by laser capture microscopy showed that both populations of cells expressed markers of stem-ness, such as Olig1, Sall2, Oct3/4, and Sox2, compared to normal brain. pSmad1-positive cells expressed high levels of SAT1 and ID1, while pSmad2-positive cells expressed high levels of EGFR (Fig. 1B).

To interrogate the conclusion that SMAD2(+) identified the proliferation fraction of glioblastoma cells, we performed double-label immunohistochemistry for pSmad1 and pSmad2 and PCNA in human glioblastoma surgical specimens (n = 4, 15 HPF/specimen). Consistent with our scRNAseq analysis, we found that only 10.1 ± 8.9% of pSmad1-positive cells were also PCNA-positive, compared to 37.6 ± 8.9% of pSmad2-positive cells, which also labeled for PCNA (Fig. 1F; p < 0.05).

Glioma stem cell phenotype is modulated by treatment with BMP4 or TGF-β. To determine if differences in cytokine signaling could in themselves account for the phenotypic divergence seen in situ, we examined the effect of TGF-β and BMP signaling on cell phenotype in three GSC lines in vitro. Treatment of GSCs with recombinant BMP4 or TGF-β resulted in a highly stereotypical and reproducible expression profile (Supplementary Fig. 2). BMP4-treated GSCs showed a greater than 2-fold decrease in cell proliferation (Fig. 2A; n = 3, p < 0.01), an effect that was significantly amplified by concomitant exposure to the TGF-β inhibitor, LY364947. Treatment with LY364949 alone had no significant effect on cell proliferation. Conversely, exposure of GSCs to TGF-β resulted in an increase in cell proliferation, with minimal amplification following concomitant exposure to the BMP antagonist, noggin (Fig. 2B; n = 3, p < 0.05). Our findings suggest that GSCs in proliferative culture secrete TGF-β. Indeed, analysis of the culture media using ELISA showed high levels of TGF-β and TGF-β, but not BMP1, BMP2, BMP4, or BMP7, under baseline culture conditions (Supplementary Fig. 3A–F).

To determine if differences in cytokine signaling could in themselves account for the phenotypic divergence seen in situ, we examined the effect of TGF-β and BMP signaling on cell phenotype in three GSC lines in vitro. Treatment of GSCs with recombinant BMP4 or TGF-β resulted in a highly stereotypical and reproducible expression profile (Supplementary Fig. 2). BMP4-treated GSCs showed a greater than 2-fold decrease in cell proliferation (Fig. 2A; n = 3, p < 0.01), an effect that was significantly amplified by concomitant exposure to the TGF-β inhibitor, LY364947. Treatment with LY364949 alone had no significant effect on cell proliferation. Conversely, exposure of GSCs to TGF-β resulted in an increase in cell proliferation, with minimal amplification following concomitant exposure to the BMP antagonist, noggin (Fig. 2B; n = 3, p < 0.05). Our findings suggest that GSCs in proliferative culture secrete TGF-β. Indeed, analysis of the culture media using ELISA showed high levels of TGF-β and TGF-β, but not BMP1, BMP2, BMP4, or BMP7, under baseline culture conditions (Supplementary Fig. 3A–F).
Figure 1. BMP and TGF-β signaling define divergent molecular identities in glioblastoma. (A) H&E and IHC for pSmad1 (BMP) and pSmad2 (TGF-β) in human glioblastoma surgical specimens (n = 9). (B) Single-cell analysis of pSmad1- and pSmad2-positive cells isolated by laser capture microscopy. (C) Unsupervised clustering of single-cell glioblastoma RNA-seq data using the most variable genes. Cell identity was determined using cell markers for pSmad1 and pSmad2-positive glioma cells. (D) Log-normalized gene expression for selected genes is shown for the SMAD1(+) and SMAD2(+) glioma cell populations identified by analysis of single-cell glioblastoma RNA-seq data. (F) Quantification of PCNA-expression in pSmad1- and pSmad2-positive cells in human glioblastoma surgical specimens (n = 4, 15 HPF/specimen; *p < 0.05).

Consistent with our in situ findings, neither BMP4 nor TGF-β1 significantly affected expression of the neural stem cell markers, Sox2 and Bmi1, in GSCs (Fig. 2C). Of note, we found that ID1 expression in GSCs was induced by treatment with BMP4 rather than TGF-β, in contrast to indirect evidence from others that ID1 is a down-stream effector of TGF-β1 in glioblastoma43. We found no difference in expression of the core GSC transcription factors Oct3/4, Sox2, SalI2, and Olig1, between GSCs treated with BMP4 or TGF-β1 (Fig. 2D). Further, BMP- and TGF-β1-treated GSCs could not be discriminated on the basis of expression of the Bernstein GSC panel of nineteen tumor-propagating cell (TPC)-specific transcription factors (Supplementary Fig. 4A)39,40. Consistently, TPCs share a BMP- and TGF-β-responsive target gene expression profile that is distinct from that of differentiated glioma cells (DGCs; Supplementary Fig. 4B). These findings suggested to us that BMP and TGF-β1 both modulate but do not abolish the GSC phenotype, and might instead control the transition of GSCs from a quiescent to a proliferative state.
BMP4 inhibits but does not abrogate GSC self-renewal and tumorigenicity. To test the hypothesis that BMP modulates but does not abolish the GSC phenotype, we examined the effect of BMP or TGF-β exposure on GSC self-renewal using the neurosphere assay system. Exposure of GSCs to TGF-β resulted in increased sphere formation by GSCs grown at clonal density (Fig. 2E; n = 3, p < 0.05), consistent with a positive effect on self-renewal, and also resulted in an increase in average sphere diameter, consistent with an increase in cell proliferation (Fig. 2F; n = 3, p < 0.01). BMP4 exposure diminished but did not abrogate sphere formation (Fig. 2E,
n = 3, N.S.), and resulted in attenuation in gliomasphere size (Fig. 2F; n = 3, p < 0.05. Further, BMP4-treated GSCs continued to form spheres with serial passaging (Fig. 2G; n = 3, N.S.), indicating that these cells remained capable of self-renewal.

We then sought to determine if BMP exposure affected GSC tumourigenic potential following orthotopic transplantation. GSCs were cultured in normal media supplemented with EGF and FGF (BT062508, BT051010, BT030909) or in media without factors and with BMP4 (BT062508-BMP4, BT051010-BMP4, BT030909-BMP4) for five days. As would be predicted by our prior studies in other GSC lines, BMP4-treated cells showed a significant decrease in proliferation, as determined by BrdU incorporation (Fig. 3A; n = 3, p < 0.01), and increased ID1 expression, with no significant change in Sox2 or nestin expression. Control and BMP4-treated GSCs were then dissociated and transplanted into the right frontal striatum of immunocompromised (NOD scid) mice (n = 5/group). As in mice transplanted with control GSCs, mice transplanted with BMP4-treated GSCs developed high-grade gliomas, though with prolonged latencies to tumour formation, compared to control cells (Fig. 3B; p < 0.01). Tumors formed by GSCs with or without BMP4 pre-treatment were histologically indistinguishable on analysis by a neuropathologist (J.F., Fig. 3C). These findings are consistent with a previous report using a transgenic mouse model that ablation of ID1 does not result in loss of tumorigenicity, but actually leads to shortened tumor latency following transplantation.[29]

**ID1 identifies a long-term label retaining cell in glioblastoma.** Our in vitro findings that BMP signaling induces quiescence in GSCs are in conflict with previous reports that BMP directs GSCs toward a terminally differentiated astroglial cell fate[30]. To distinguish between these two opposing hypotheses, we performed two long-term label retaining cell (LRC) assay studies in a glioblastoma xenograft model.[42] The LRC assay exploits the dynamics of integration and retention of a tagged synthetic nucleoside into the DNA through the cell cycle. The tag will only be found in cells that have undergone DNA replication during a period overlapping that of delivery of the synthetic nucleoside. Further, the signal will diminish as that cell undergoes further cell divisions. For our experiments, we employed the nucleoside analog 5-ethynyl-2′-deoxyuridine, marked with a fluorescent tag (EdU-FITC; Invitrogen).

We first sought to determine if BMP-activated glioma cells differ in their likelihood to enter the cell cycle compared with the TGF-β-activated glioma cells that make up the most of the tumor bulk. To do so, mice harboring a mature glioblastoma xenograft were administered a single dose of EdU through intraperitoneal injection and then sacrificed at successive time points thereafter (Fig. 4A; n = 3/time point). In this paradigm, EdU labeling will be limited to cells entering or within the cell cycle at the time of its administration. The label will rapidly decay in cells that go on to re-enter the cell cycle. ID1 was used as a proxy for BMP activation, while we used phosphorylated Smad2 as a marker of TGF-β activation. At 1 hour following EdU administration, 13.4 ± 5.3% of ID1-positive cells were also EdU-positive (Fig. 3B), compared to 78.8 ± 21.4% of pSmad2-positive cells (Fig. 4B; p < 0.001). By 14 days, 34.6 ± 3.7% of ID1-positive cells were EdU-positive, compared to 4.1 ± 0.5% of pSmad2-positive cells (p < 0.001). Time-point analysis showed rapid decay of EdU signal from pSmad2-positive
Figure 4. ID1 identifies a long-term label retaining cell in glioblastoma. (A) Schematic of chase following a single intraperitoneal injection of EdU in NSG mice harboring BT046 intracranial xenograft tumors (n = 3/time point). (B) Quantification of relative frequency of EdU positivity in ID1- and pSmad2-positive cells (*p < 0.001). (C) Schematic of chase following a 7-day continuous load with EdU in NSG mice harboring BT046 intracranial xenograft tumors. (D) Quantification of relative frequency of EdU positivity in ID1- and pSmad2-positive cells (*p < 0.001).

cells, with no significant loss of signal from ID1-positive cells, consistent with a divergence in cell cycle entry between BMP-activated and TGF-β-activated glioma cells.

We then sought to determine if BMP-activated glioma cells are LRCs. To do so, we employed a paradigm in which mice were administered EdU for 7 days, which should result in labeling of most if not all mitotically active cells within the tumour, followed by a long-term chase (Fig. 4C; n = 3/time point). Mice were sacrificed and brain tissues collected on days 7, 14, and 21, following completion of EdU administration, or at endpoint. The frequency of EdU/ID1 and EdU/pSmad2 double-positive cells was quantified from primary tumor sections throughout the labeling and chase. At the initial time-point, we found that 8.8 ± 4.1% of ID1-positive cells were EdU-positive, compared to 55.0 ± 5.5% of pSmad2-positive cells (Fig. 4D; p < 0.001)). By 21 days, 43.3 ± 10.8% of ID1-positive cells were EdU-positive, compared to 67.0 ± 4.0% of pSmad2-positive cells (p < 0.001). Time-point analysis demonstrated that EdU signal steadily reduced in the pSmad2-positive population. Surprisingly, the percentage of ID1-positive cells that were also EdU-positive increased during the chase, suggesting that some of the cells in this population may have transitioned to no longer express ID1. Taken together, these studies demonstrate that BMP pathway activation demarcates a slow cycling, long-term label retaining cell population in glioblastoma.

pSmad1 identifies a pool of treatment-resistant glioma cells. LTR cells are thought to constitute a treatment-resistant cell population in multiple hematopoietic and solid cancer subtypes, including acute lymphoblastic leukemia43, pancreatic cancer44, colorectal cancer45, and breast cancer46. To determine if BMP-activated (pSmad1+) glioma cells could constitute a treatment-resistant cell population in glioblastoma, we performed IHC from paired human glioblastoma specimens harvested at initial diagnosis and immediately following radiation and temozolomide chemotherapy. As clinical practice does not conventionally allow for harvest immediately following completion of adjuvant therapy, our analysis was limited to three patients in whom tissue harvest at this point was driven by concern of early relapse. At both time points, we analyzed regions corresponding to sites of Gadolinium contrast enhancement on magnetic resonance imaging (Supplementary Fig. 5A–C). At initial diagnosis, pSmad2+ cells constituted the majority of identified tumor cells, while pSmad1+ cells constituted a small minority, in all three patients (Fig. 5A; p < 0.01). Conversely, analysis of biopsy specimens harvested at the immediate conclusion of radiation and temozolomide chemotherapy showed a significant increase in the pSmad1+ cell population, as well as a significant decrease in the pSmad2+ cell population (Fig. 5B; p < 0.01).

We were then able to identify one patient in whom paired tumor samples were available from the time of initial diagnosis, immediately following completion of adjuvant therapy, and at frank radiographic recurrence (Supplementary Fig. 6). In this single patient, analysis at initial diagnosis showed that the majority of glioma cells were marked by pSmad2, while only a minority of cells were found to be pSmad1-positive (Fig. 5C; p < 0.01). As found in our first cohort, analysis of analysis of biopsy specimens harvested at the immediate conclusion of radiation and temozolomide chemotherapy showed a significant increase in the pSmad1+ cell population, as well as a significant decrease in the pSmad2+ cell population (Fig. 5D; p < 0.01). Interestingly, analysis of tumor tissue harvested at the time of frank recurrence once again showed an abundance of pSmad2+ cells (Fig. 5E; p < 0.01).

Finally, we analyzed publicly available scRNA data from a primary glioblastoma and matched recurrence (n = 43 single cells, 27 cells at initial diagnosis and 16 cells at recurrence)47. While the sample contained too few cells to allow for meaningful unsupervised clustering, differential expression of analysis of cells at recurrence revealed a trend toward enrichment of the SMAD1(+) glioma cells markers, ID1 and SAT1, and a statistically significant loss of the SMAD2(+) glioma cell markers, EGFR and SALL2 (Fig. 5F). These data suggest that
pSmad1+ cells are enriched by radiation and temozolomide chemotherapy, and could serve as a reservoir for tumor recurrence.

**Activation of the BMP signaling pathway protects glioma cells from cytotoxic injury.** To examine if BMP activation could account for treatment resistance in glioblastoma cells, we performed in vitro survival studies in three GSC lines (G144, G179, BT046) exposed to a five-day course of temozolomide (25 μM) and concomitant radiation (10 Gy/5 sessions) following treatment with BMP or TGF-β pathway agonists. As expected, treatment of GSCs with temozolomide and radiation resulted in substantial cell death. The cytotoxic effect of temozolomide and radiation was significantly attenuated by pre-treatment of GSCs with BMP4, while pre-treatment with TGF-β significantly increased the amount of cell death that occurred with cytotoxic therapy (Fig. 6A–C; n = 3, p < 0.05). Treatment of GSCs with BMP4 resulted in increased expression of the DNA repair protein, O6-methylguanine DNA methyltransferase (MGMT), as well as increased phospho-activation of the

**Figure 5.** pSmad1 identifies a pool of treatment-resistant glioma cells. (A) Quantification of pSmad1- and pSmad2-immunopositivity in glioblastoma specimens harvested from patient 64, patient 223, and patient 286, at initial diagnosis (*p < 0.01). (B) Quantification of pSmad1- and pSmad2-immunopositivity in glioblastoma specimens harvested from patient 64, patient 223, and patient 286, during chemoradiation with temozolomide (*p < 0.01). (C–E) Quantification of pSmad1- and pSmad2-immunopositivity in glioblastoma specimens harvested from a single patient at initial diagnosis, during chemoradiation with temozolomide, and at frank recurrence (*p < 0.01). (F) Differential expression analysis (Wilcoxon-rank sum test) of single cell glioma RNA-seq data from a single patient at initial diagnosis (T01) and tumor recurrence (T01.R) (n = 43 single cells, 27 cells at initial diagnosis and 16 cells at recurrence).
DNA repair modulator, ATM serine/threonine kinase (ATM) (Fig. 6D). Finally, treatment of GSCs with BMP4 resulted in decreased expression of the DNA damage mark, gamma-H2AX phosphorylation (pH2AX), in GSCs following exposure to temozolomide and radiation (Fig. 6E).

Disease relapse in acute myeloid leukemia after conventional chemotherapy is thought to be caused by quiescent leukemic stem cells, which are able to survive cytotoxic therapy and drive disease recurrence. We hypothesized that treatment resistance in glioblastoma could also be mediated by relative cell quiescence. To test this hypothesis, we developed temozolomide-resistant cell lines using U251 and ID1−/−/U251.1/2 cells. The parental cells were cultured with a biweekly increasing dose of temozolomide, starting at 10 µM to a maximum dose of 200 µM. A selected population of U251 cells survived this treatment (U251 temozolomide-resistant cell line; Fig. 6C). We characterized the molecular profile of these cells using microarray analysis and identified a set of genes that were upregulated in U251-TR cells compared to U251 cells (Fig. 6H).
U251.TR) and were definably temozolomide resistant, as determined by IC50 and TMZ sensitivity assay for viability following treatment (Supplementary Fig. 7A,B). Compared to parental U251 cells, U251.TR cells had no significant change in proliferation rate in vitro (Supplementary Fig. 7C). However, while U251.TR tumors were histologically indistinguishable from tumors formed by their parental counterparts (Supplementary Fig. 7D,E), they had an increased latency of tumor formation following intracranial implantation in immunocompromised mice (Fig. 6F; p < 0.01). Further, expression analysis showed that U251.TR cells exhibit a BMP activation signature (Fig. 6G), in contrast to parental U251 cells, which exhibit a TGF-β activation signature (Fig. 6H).

**p21 mediates the effects of BMP4 as an anti-proliferative and cytoprotective signal in glioblastoma.** To determine the mechanism by which GSCs transition from a quiescent to an activated state, we performed expression profiling of these two populations in vitro. Among the genes that showed a change in expression in the BMP- and TGF-β-treated groups was p21. We were particularly interested in this transcript because of its role in mediating activation states in NSCs. In adult mice, p21 has been shown to regulate NSC self-renewal and proliferation, and selected knockout of p21 results in NSC exhaustion49,50. Forced expression of p21 results in NSC quiescence, and protects NSCs from senescence45. First, using Western blot analysis, we found only minimal expression of p21 in U251 glioblastoma cells in resting-state culture. p21 expression begins to increase within 4 hours of treatment with BMP4, and peaks by 24 hours of BMP exposure (Fig. 7A). The effect of BMP4 on p21 appears to be through induction of transcription at the CDKN1A gene, as demonstrated by increased luciferase activity following U251 transfection with a full-length p21 promoter reporter and treatment with BMP4 (Fig. 7B; n = 3).

We then wished to determine if p21 expression is sufficient and necessary for the anti-proliferative effect of BMP in glioblastoma. To do so, we first examined the effect of p21 inhibition on U251 cell proliferation, using siRNA-mediated knockdown of p21. Knockdown of p21 in U251 cells using siRNA resulted in a negligible increase in U251 proliferation, compared to control, but had a significant effect in mitigating the negative effects of treatment with BMP4 on proliferation (Fig. 7C; n = 3). We then studied the effect of p21 expression on U251 cell proliferation following transfection with a wild-type p21 overexpression vector. Exogenous p21 expression in U251 cells resulted in decreased proliferation, an effect that was not significantly changed by subsequent treatment with BMP4 or TGF-β1 (Fig. 7D; n = 3).

We then sought to elucidate the mechanisms by which p21 inhibits proliferation in glioblastoma. p21 has been shown to bind to and inhibit the oncogenic transcription factor, Stat3, a known target of TGF-β in glioblastoma and driver of GSC self-renewal and proliferation23,25. As predicted, coimmunoprecipitation assays demonstrated evidence of p21-Stat3 complex formation in U251 cells treated with BMP4, but not in U251 cells in resting-state culture, which was inhibited by treatment with the chemical p21 inhibitor, sterigmatocystin (Fig. 7E). Our findings demonstrate that p21 binds to Stat3 in U251 cells following activation of the BMP signaling pathway.

Finally, we wished to determine if p21 expression is necessary for BMP to protect glioma cells from temozolomide cytotoxicity. To do so, we generated IC50 curves for temozolomide in U251 cells treated with BMP and scrambled siRNA or BMP and p21 siRNA, compared to scrambled siRNA alone (Fig. 7F; n = 3, p < 0.05). Treatment of U251 cells with BMP4 and scrambled siRNA resulted in a rightward shift of the temozolomide IC50 curve, consistent with a protective effect of BMP4 against temozolomide cytotoxicity in glioma cells. This protective effect was negated by concomitant treatment of U251 cells with BMP4 and siRNA against p21. Our findings support the conclusion that p21 mediates the effect of BMP4 as an inhibitor of cell proliferation and a mediator of temozolomide resistance in glioblastoma.

**Discussion**

 Taken together, our results demonstrate a subpopulation of quiescent GSCs in glioblastoma, and show that GSC quiescence and activation are mediated by BMP and TGF-β signaling, through the downstream targets, ID1 and p21. These findings speak to the functional heterogeneity of the cancer stem cell identity, and suggest that treatments designed to target CSCs must negotiate differences between these two subpopulations. As in the adult NSC niche, BMP signaling in the glioblastoma microenvironment directs GSCs toward a quiescent state, rather than toward a differentiated, astroglial cell fate, in a process reproducible through expression of p21.

Current studies suggest that cell quiescence is not a passive state, but rather a reversible G0 phase functional phenotype that requires active maintenance and regulation, and from which cells may be activated to re-enter the cell cycle44. A study of the mouse adult NSC niche of the subgranular zone (SGZ), for example, revealed two groups of adult NSCs: active NSCs that express proliferating cell nuclear antigen (PCNA) and can be identified by a 1-day BrdU pulse, and BrdU-retaining quiescent adult NSCs45. The presence of two NSC populations within the NSC niche may speak to the physiologic need to maintain a viable NSC pool; in another study finding that NSC quiescence in the SGZ was maintained by the BMP receptor, BMPR1a, inhibition or ablation of BMP signaling resulted in a temporal increase in progenitor proliferation and subsequent decrease of neurogenesis due to exhaustion of the stem cell pool46.

Whether there is a similar need for a quiescent stem-like cell pool to maintain the non-physiologic hierarchy of cancer systems is unclear. Quiescent CSCs have been identified in multiple tumors, including pancreatic adenocarcinoma37, breast cancer38, liver cancer39, and melanoma40. Further, studies from multiple cancer systems give evidence to a role for quiescent cells in treatment resistance. Current studies suggest that cell quiescence is not a passive state, but rather a reversible G0 phase functional phenotype that requires active maintenance and regulation, and from which cells may be activated to re-enter the cell cycle44.

For example, targeting of S phase cells in an in vivo liver tumor model using concomitant treatment with a CD13 inhibitor and 5 fluorouracil (5-FU) resulted in a more significant decrease in tumor volume than was seen with treatment with either drug alone39. Similarly, JARD1B knockdown to target slow cycling cells in a melanoma animal model results in significant inhibition of tumor growth and progression of tumor metastases40.
Finally, in an animal model of glioblastoma, treatment with the chemotherapeutic agent, temozolomide, resulted in an enrichment of relatively quiescent stem-like cells, which were able to drive tumor recurrence.

In our study, treatment of GSCs in vitro with BMP4 or TGF-β1 directed GSCs toward a quiescent or activated phenotype, respectively. Our in vitro studies show that the anti-proliferative effect of BMP4 on glioma cells is mediated by its downstream targets, ID1 and p21. In vivo, staining for ID1 identifies a label-retaining cell population in a glioblastoma patient-derived xenograft tumor, supporting the conclusion based on pSmad1 and PCNA co-staining studies in human glioblastoma surgical specimens, that the BMP signaling pathway maintains a quiescent cell population in glioblastoma. Further, BMP signaling exerts a protective effect on glioma cells from temozolomide chemotherapy and radiation, while inhibition of BMP signaling enhances the cytotoxic effects of temozolomide and radiation. Whether glioblastoma cells in vivo exhibit functional plasticity in response to cell extrinsic signals as they do in vitro, and whether quiescent cell populations contain critical pools of treatment-resistant cells, remains to be elucidated.

**Ethics approval and consent to participate.** All studies involving human subjects or tissue were approved by the Research Ethics Board at St. Michael’s Hospital, the Hospital for Sick Kids, and the University of Toronto, or the Institutional Review Board of Northwestern University. All animal studies were performed within...
the guidelines of an approved Animal Use Protocol at The Centre for Phenogenomics, University of Toronto or Northwestern University.

Consent for publication. Deidentified patient imaging data have been included in study under the auspices of the Research Ethics Board at St. Michael’s Hospital.

Methods

Human samples and study approval. Human glioblastoma specimens and clinical data (including radiographic imaging) were obtained from St. Michael’s Hospital, the St. Michael’s Hospital Brain Tumour Biobank and Clinical Database, and Northwestern Memorial Hospital, following approval by the Institutional Research Ethics Boards of both institutions. Informed consent was obtained from all participants prior to the use of tissue samples or clinical data. All samples were de-identified before analysis. All methods were performed in accordance with the guidelines and regulations of the Research Ethics Boards of St. Michael’s Hospital and Northwestern Memorial Hospital.

TCGA Analysis. Normalized RNA-expression data on the Affymetrix U133A platform was downloaded from the TCGA data portal. Differentially expressed genes related to TGF and BMP signalling were compared to each subclass of GBM using ANOVA followed by a Post-Tukey analysis. Significance was established at \( p < 0.05 \).

Glioma stem cells and patient-derived xenografts. The GSC lines BT818, BT062508, BT051010, and BT063008 were cultured as neurospheres in Neurocult NS-A Basal Medium (Human Stem Cell Technologies), supplemented with 2mM L-glutamine (Invitrogen), 1X antibiotic/antimycotic (Invitrogen), 1% N2 supplement (Gibco), 2% B27 supplement (Gibco), 75 ng/ml bovine serum albumin (BSA, Sigma), 20ng/ml human epidermal growth factor (hEGF, Sigma) and 20 ng/ml human basic fibroblast growth factor (hFGF, Sigma).

The GSC lines BT2012035, BT2012087, 101007, 041507, G144, G179, and GliNS1 were cultured and maintained in stem-like media as an adherent monolayer as previously described (Pollard et al., Cell Stem Cell 2009). Briefly, these cell lines were cultured in Neurocult NS-A Basal Medium (Human Stem Cell Technologies), supplemented with 2mM L-glutamine (Invitrogen), 1X antibiotic/antimycotic (Invitrogen), 1% N2 supplement (Gibco), 2% B27 supplement (Gibco), 75 ng/ml bovine serum albumin (BSA, Sigma), 20 ng/ml human epidermal growth factor (hEGF, Sigma) and 20 ng/ml human basic fibroblast growth factor (hFGF, Sigma).

NOD scid gamma (NSG) mice were purchased from the Jackson Laboratory and maintained in accordance with Toronto Centre for Phenogenomics (TCP) institutional animal protocol. All experimental protocols were approved by the animal utilization committee at TCP. NSG mice underwent stereotactic intracranial injections of \( 1.5 \times 10^5 \) BT818 cells into the right corpus striatum, at coordinates 1 mm lateral and 1 mm anterior of the bregma suture, at a depth of 2.5 mm. Following confirmation of tumor formation, mice were treated with EdU and sacrificed at successive time points thereafter.

Single-cell RNA sequencing analyses. Analysis of scRNA-seq datasets was performed using the R-package Seurat [PMID: 29608179]. The two single-cell datasets were separately analyzed. First, log-normalized single-cell gene expression data was downloaded from 5 patients with primary glioblastoma (\( n = 430 \) single cells) [PMID:24925914]. The 5,948 genes with highest expression were available for analysis. The most variably expressed genes were determined accounting for the average expression and dispersion of each gene (\( n = 585 \) genes). Principal component analysis was performed using the most variable genes followed by t-distributed stochastic neighbor embedding (t-SNE) for dimensionality reduction and cluster identification. Assignment of cell type identity to clusters was determined using the genes defined in the single-cell qPCR analyses (OLIG1, BM1, EGFR), cell cycle marker genes (TOP2A, PCNA), or pathway-related genes when expression for marker genes were unavaiable (ID3, ID2, BMPS, NES). Enrichment analysis for gene ontology was performed using the Bioconductor package “topGO”.

A second dataset included scRNA-seq from the same patient at two separate timepoints, the primary tumor (T01, \( n = 27 \)) and recurrent (T01.R, \( n = 16 \)) [PMID: 28263318]. Data were processed as described above. Wilcoxon rank-sum tests were used to assess differential expression between the primary and recurrent tumor.

Tissue culture. Cells were treated with 20ng/mL BMP4 (R&D System), 250ng/mL noggin (R&D System), 20 ng/mL TGF-β1 (R&D System), 3 μM LY364947 (Sigma), and 10 μM BrdU labeling solution (Roche), as described.

Neurosphere formation efficiency assay. GSCs were plated at various densities (100–2000 cells/mL) in serum-free media and cultured for 7 days. Spheres were defined being of diameter greater than 100 μm. All experiments were performed in triplicate.

Cell proliferation assay. Cell growth was assayed by plating 5000 cells per well in a TC-treated 96-well clear bottom plate (Corning). Plates were collected at the reported time points and assayed using Alamar Blue as per manufacturer’s protocol. Cell growth was assayed by plating 1 × 10^4 cells per well in a TC-treated 6-well plate (Corning). Plates were collected at the reported time points and cells were counted using ViCell cell counter.

Immunohistochemistry. Human glioblastoma specimens and clinical data were obtained from the St. Michael Hospital Brain Tumour Biobank following approval by the Institutional Research Ethics Boards. All samples were de-identified before analysis. Tissue samples were preserved in 10% formalin, dehydrated and embedded in paraffin. Five μm sections were immunostained for pSmad1/5 (Abcam; 1:100), pSmad2 (Cell Signaling; 1:100), or PCNA (Abcam; 1:1000) with antigen retrieval using pressure cooking in 10uM citrate buffer at pH6.0,
secondary HRP anti-Rabbit IgG (Vector Laboratories; 1:250), and detection using DAB Substrate kit (Vector lab). Primary antibodies Nuclei were counterstained with DAPI (Sigma; 0.002 mg/ml) for 10 minutes, washed and mounted with Vectashield mounting medium (Vector Laboratories). Images were acquired with a Quorum Spinning Disk Confocal Microscope (Olympus) running Volocity software (Perkin Elmer).

**Western blotting.** Cells were washed with cold PBS and lysed. Cell lysates were shaken at 4°C for 10 min and centrifuged at 14,000 \( \times g \) for 10 min. Protein concentrations in the supernatants were quantified using the BCA protein assay. Fifteen micrograms of protein were separated on 10% acrylamide/bisacrylamide gels and transferred to PVDF membranes. PVDF membranes and blocked with 5% (w/v) skim milk in PBS/0.1% Tween-20 for 1 h at room temperature. Membranes were blotted with Sox2, Bmi1, nestin, GFAP, Oct3/4, Sall2, Olig1, p21, Stat3, or actin, at 4°C overnight, then washed and incubated with secondary antibodies (Cell Signaling) for 1 h at room temperature. Bound antibodies were detected with horseradish peroxidase-linked anti-mouse or anti-rabbit IgG (Cell Signaling), followed by ECL (Amersham). Protein quantification was performed by densitometry (Image Studio, LI-COR). Protein levels were normalized for \( \beta\text{-actin} \).

**Quantitative real-time PCR.** Total RNA was extracted from cells in culture using an RNAEasy Kit according to the manufacturer’s instructions (Qiagen), and cDNA synthesis was performed using SuperScript II (Invitrogen). Assays were performed using SYBR Green PCR Master Mix (Applied Biosystems) with a StepOne Real Time PCR System. Predesigned primers were purchased from IDT. Gene transcript levels were calculated using the \( \Delta\Delta^{CT} \) method.

**Microarray analysis.** Gene expression profiles were measured by Affymetrix GeneChip Human Transcriptome Array 2.0, and RMA normalization was applied. The probe set profiles were summarized to gene level expression profiles by selecting a probe set with maximal IQR (interquartile range) when multiple probe sets were mapped to a gene. Discriminative genes for three groups (BMP4, GSC, and TGF-\( \beta \)) were identified by Mann-Whitney U-test. The genes in the heat map were selected by Mann-Whitney U-test with a criteria of \( p < 0.05 \). Gene expression profile for each gene was normalized so that minimal value and maximal value could be converted to 0 and 1, respectively.

**Short interfering RNA knockdown.** Predesigned short interfering (si)RNAs targeting human p21 and scrambled control siRNAs were purchased from Qiagen. Two separate siRNAs targeting different sequences within p21 were used to transfect U251 cells using Lipofectamine 2000 (Invitrogen) versus scrambled control siRNA. Cells were harvested 48 hours post-transfection for analysis of protein and RNA levels.

**Statistical analysis.** GraphPad Prism 7 software was used to analyze results. Significance was determined by a 2-tailed Student’s t-test.

**Statement of translation significance.** Glioblastoma is the most prevalent and aggressive malignant brain tumour in adults, with a median survival following multi-modality therapy of 14.6 months. Recent studies have implicated cancer stem cells within glioblastoma (glioma stem-like cells, GSCs) as mediators of tumor growth, therapeutic resistance and tumor progression. In our work, we characterize the role of the BMP and TGF-\( \beta \) signaling pathways as regulators of CSC state in glioblastoma. We find that BMP pathway activation confers relative resistance to radiation and temozolomide chemotherapy, and defines a quiescent cell population in patients that is enriched by temozolomide chemoradiotherapy. Our study identifies a cellular reservoir for tumor recurrence in glioblastoma following cytotoxic therapy and provides a target to prolong treatment response.

**Data Availability**
Sequence data has been deposited at the European Genome-phenome Archive (EGA), which is hosted by the EBI and the CRG.

**References**

1. Stupp, R. *et al.* Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *The New England journal of medicine* **352**, 987–996, https://doi.org/10.1056/NEJMoa043330 (2005).
2. Chen, J. *et al.* A restricted cell population propagates glioblastoma growth after chemotherapy. *Nature* **488**, 522–526, https://doi.org/10.1038/nature11287 (2012).
3. Bao, S. *et al.* Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. *Nature* **444**, 756–760, https://doi.org/10.1038/nature05236 (2006).
4. Jin, X. *et al.* Targeting glioma stem cells through combined BMI1 and EZH2 inhibition. *Nature medicine* **23**, 1352–1361, https://doi.org/10.1038/nm.4415 (2017).
5. Cheng, L. *et al.* Elevated invasive potential of glioblastoma stem cells. *Biochemical and biophysical research communications* **406**, 643–648, https://doi.org/10.1016/j.bbrc.2011.02.123 (2011).
6. Lee, J. *et al.* Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. *Cancer cell* **9**, 391–403, https://doi.org/10.1016/j.ccr.2006.03.030 (2006).
7. Pollard, S. M. *et al.* Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. *Cell stem cell* **4**, 568–580, https://doi.org/10.1016/j.stem.2009.03.014 (2009).
8. Li, L. & Clevers, H. Coexistence of quiescent and active adult stem cells in mammals. *Science* **327**, 542–545, https://doi.org/10.1126/science.1180794 (2010).
9. Genander, M. *et al.* BMP signaling and its pSMAD1/5 target genes differentially regulate hair follicle stem cell lineages. *Cell stem cell* **15**, 619–633, https://doi.org/10.1016/j.stem.2014.09.009 (2014).
10. Codega, P. *et al.* Prospective identification and purification of quiescent adult neural stem cells from their *in vivo* niche. *Neuron* **82**, 545–559, https://doi.org/10.1016/j.neuron.2014.02.039 (2014).
49. Kippin, T. E., Martens, D. J. & van der Kooy, D. p21 loss compromises the relative quiescence of forebrain stem cell proliferation.

48. Fujita, S.

46. Akrap, N.

45. Xin, H. W.

44. Li, D.

43. Ebinger, S.

42. Wilson, A.

41. Suva, M. L.

40. Piccirillo, S. G. M.

39. Assanah, M.

38. Anido, J.

37. Soroceanu, L.

36. Kebebew, E., Treseler, P. A., Duh, Q. Y. & Clark, O. H. The helix-loop-helix transcription factor, Id-1, is overexpressed in medullary thyroid cancer. *Surgery* **128**, 952–957, https://doi.org/10.1067/msy.2000.111082 (2000).

35. Kreso, A. et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. *Science* **339**, 543–548, https://doi.org/10.1126/science.1237670 (2013).

34. O’Brien, C. A. et al. Id1 and Id3 regulate the self-renewal capacity of human colon cancer-initiating cells through p21. *Cancer cell* **21**, 777–792, https://doi.org/10.1016/j.ccr.2012.04.036 (2012).

33. Soroceneau, L. et al. Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target. *Cancer research* **73**, 1539–1569, https://doi.org/10.1158/0008-5472.CAN-12-1943 (2013).

32. Anido, J. et al. TGF-beta Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. *Cancer cell* **18**, 655–668, https://doi.org/10.1016/j.ccr.2010.10.023 (2010).

31. Barrett, L. E. et al. Self-Renewal Does Not Predict Tumor Growth Potential in Mouse Models of High-Grade Glioma. *Cancer cell* **21**, 11–24, https://doi.org/10.1016/j.ccr.2011.11.025 (2012).

30. Oshimori, N. & Fuchs, E. The harmonies played by TGF-beta in stem cell biology. *Cell stem cell* **11**, 751–764, https://doi.org/10.1016/j.stem.2012.11.001 (2012).

29. Oshimori, N. & Fuchs, E. Paracrine TGF-ß&beta; and Id1: Signaling Counterbalances BMP-Mediated Repression in Hair Follicle Stem Cell Activation. *Cell stem cell* **10**, 63–75, https://doi.org/10.1016/j.stem.2011.11.005 (2012).

28. Keyes, B. E. et al. Nfatc1 orchestrates aging in hair follicle stem cells. *Proceedings of the National Academy of Sciences of the United States of America* **110**, E4950–4959, https://doi.org/10.1073/pnas.1320301110 (2013).

27. Jankovic, V. et al. Id3 restrains myeloid commitment, maintaining the self-renewal capacity of hematopoietic stem cells. *Proceedings of the National Academy of Sciences of the United States of America* **104**, 1260–1265, https://doi.org/10.1073/pnas.0707894104 (2007).

26. Perry, S. S. et al. Id1, but not Id3, directs long-term repopulating hematopoietic stem-cell maintenance. *Blood* **110**, 2351–2360, https://doi.org/10.1182/blood-2007-01-069914 (2007).

25. Assanah, M. et al. Giall progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retrometuzases. *The Journal of neuroscience: the official journal of the Society for Neuroscience* **26**, 6781–6790, https://doi.org/10.1523/JNEUROSCI.0514-06.2006 (2006).

24. Piccirillo, S. G. M. et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. *Nature* **444**, 761–765, https://doi.org/10.1038/nature05349 (2006).

23. Bruna, A. et al. High TGFß/-Smad Activity Confers Poor Prognosis in Glioma Patients and Promotes Cell Proliferation Depending on the Methylation of the PDGF-B Gene. *Cancer cell* **11**, 147–160, https://doi.org/10.1016/j.ccr.2006.11.023 (2007).

22. Peñuelas, S. et al. TGF-ß&beta; and Id1: Increases Glioma-Initiating Cell Self-Renewal through the Induction of LIF in Human Glioblastoma. *Cancer cell* **15**, 315–327, https://doi.org/10.1016/j.ccr.2009.02.011 (2009).

21. Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. *Science* **344**, 1396–1401, https://doi.org/10.1126/science.1254257 (2014).

20. Suva, M. L. et al. Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. *Cell* **157**, 580–594, https://doi.org/10.1016/j.cell.2014.02.030 (2014).

19. Anido, J. et al. TGF-ß&beta; and Id1: Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. *Cancer cell* **18**, 655–668, https://doi.org/10.1016/j.ccr.2010.10.023 (2010).

18. Wilson, A. et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. *Cell* **135**, 1118–1129, https://doi.org/10.1016/j.cell.2008.10.048 (2008).

17. Ebinger, S. et al. Characterization of Rare, Dormant, and Therapy-Resistant Cells in Acute Lymphoblastic Leukemia. *Cancer cell* **30**, 849–862, https://doi.org/10.1016/j.cccel.2016.11.003 (2016).

16. Li, D. et al. Loss of PDPK1 abrogates resistance to gemcitabine in label-retaining pancreatic cancer cells. *BMC Cancer* **18**, 772, https://doi.org/10.1186/s12885-018-4690-1 (2018).

15. Xin, H. W. et al. Tumor-initiating label-retaining cancer cells in human gastrointestinal cancers undergo asymmetric cell division. *Stem Cells* **30**, 591–598, https://doi.org/10.1002/stem.1061 (2012).

14. Akrap, N. et al. Identification of Distinct Breast Cancer Stem Cell Populations Based on Single-Cell Analyses of Functionally Enriched Stem and Progenitor Pools. *Cell stem cells* **6**, 121–136, https://doi.org/10.1016/j.stem.2015.12.006 (2016).

13. Lee, J. K. et al. Spatiotemporal genomic architecture informs precision oncology in glioblastoma. *Nat Genet* **49**, 594–599, https://doi.org/10.1038/ng.3806 (2017).

12. Fujiita, S. et al. Dual inhibition of EZH2/1 breaks the quiescence of leukemia stem cells in acute myeloid leukemia. *Leukemia* **32**, 855–864, https://doi.org/10.1038/leu.2017.300 (2018).

11. Kippin, T. E., Martens, D. J. & van der Kooy, D. p21 loss compromises the relative quiescence of forebrain stem cell proliferation leading to exhaustion of their proliferation capacity. *Genes & development* **19**, 756–767, https://doi.org/10.1101/gad.2127305 (2005).
50. Porlan, E. et al. Transcriptional repression of Bmp2 by p21(Waf1/Cip1) links quiescence to neural stem cell maintenance. *Nature neuroscience* **16**, 1567–1575, https://doi.org/10.1038/nn.3545 (2013).

51. Marques-Torrejon, M. A. et al. Cyclin-dependent kinase inhibitor p21 controls adult neural stem cell expansion by regulating Sox2 gene expression. *Cell stem cell* **12**, 88–100, https://doi.org/10.1016/j.stem.2012.12.001 (2013).

52. Coqueret, O. & Gascan, H. Functional interaction of STAT3 transcription factor with the cell cycle inhibitor p21WAF1/CIP1/SDI1. *J Biol Chem* **275**, 18794–18800, https://doi.org/10.1074/jbc.M001460120 (2000).

53. Rahaman, S. O. et al. Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. *Oncogene* **21**, 8404–8413, https://doi.org/10.1038/sj.onc.1206047 (2002).

54. Cheung, T. H. & Rando, T. A. Molecular regulation of stem cell quiescence. *Nature reviews. Molecular cell biology* **14**, 329–340, https://doi.org/10.1038/nrm3591 (2013).

55. Lugert, S. et al. Quiescent and active hippocampal neural stem cells with distinct morphologies respond selectively to physiological and pathological stimuli and aging. *Cell stem cell* **6**, 445–456, https://doi.org/10.1016/j.stem.2010.03.017 (2010).

56. Mira, H. et al. Signaling through BMPR-IA regulates quiescence and long-term activity of neural stem cells in the adult hippocampus. *Cell stem cell* **7**, 78–89, https://doi.org/10.1016/j.stem.2010.04.016 (2010).

57. Dembinski, J. L. & Krauss, S. Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma. *Clinical & experimental metastasis* **26**, 611–623, https://doi.org/10.1007/s10585-009-9260-0 (2009).

58. Pece, S. et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. *Cell* **140**, 62–73, https://doi.org/10.1016/j.cell.2009.12.007 (2010).

59. Haraguchi, N. et al. CD13 is a therapeutic target in human liver cancer stem cells. *J Clin Invest* **120**, 3326–3339, https://doi.org/10.1172/JCI42411 (2010).

60. Roesch, A. et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. *Cell* **141**, 583–594, https://doi.org/10.1016/j.cell.2010.04.020 (2010).

Acknowledgements

S.D. is supported by grants and awards from the Canadian Institutes of Health Research (CIHR-OG-341329) and by an Early Research Award from the Province of Ontario. A.C. was supported by the CIHR Canada Graduate Scholarship.

Author Contributions

R.S., M.W., A.C. and U.S. performed molecular and cell biology experiments and analyzed the data. A.C. and M.S.G. performed animal studies. K.J. and H.K. performed the bioinformatics studies. J.H.C., M.B. and R.V. interpreted the bioinformatics studies. J.A.K. assisted in conceptualization and design of the study. J.K. performed all pathologic analysis. S.D. conceptualized and designed the study and wrote the initial manuscript. All authors read and approved the final manuscript.

Additional Information

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-51270-1.

Competing Interests: The authors declare no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019